Table 2 Phase 2 studies of PTX-based preoperative neoadjuvant chemoradiotherapy for EC patients
Authors | Cases (SC/AC/other) | Chemotherapy | Radiation dose (Gy) | Median survival (months) | pCR | ||
|---|---|---|---|---|---|---|---|
Total | SC | AC | |||||
Safran, et al. [26] | 41 (12/29) | PTX 60 mg/m2 3 h; DDP 25 mg/m2 d1, 8, 15, 22 | 39.6 | 15 | 29% | 42% | 24% |
Bains, et al. [27] | 41 (16/25) | Induction, DDP 75 mg/m2; PTX 175 mg/m2, W 1, 4; Concurrent, DDP 30 mg/m2/w; PTX 30–80 mg/m2/w, 96 h civ w 7–12 | 50.4 | – | 22% | 31% | 16% |
Urba, et al. [28] | 69 (10/57/2) | DDP 75 mg/m2 d1; PTX 60 mg/m2 d1, 8, 15, 22 | 45 | 24 | 19% | – | – |
Van Meerten, et al. [29] | 54 (12/41/1) | PTX 50 mg/m2, d1, 8, 15, 22, 29; CBP AUC = 2, d1, 8, 15, 22, 29 | 41.4 | – | 25% | – | – |
Meluch, et al. [30] | 129 (35/91/3) | PTX 200 mg/m2, 1 h, d1, 22; CBP AUC = 4, d1, 22; 5-FU 225 mg/m2/d, civ, d1–42 | 45 | 22 | 38% | 53% | 37% |
Lin, et al. [31] | 97 (92/5) | PTX 35 mg/m2, 1 h, d1, d4; DDP 15 mg/m2 d2, d5 | 40 | 29 | 25% | – | – |
Jatoi, et al. [32] | 54 (−/−) | PTX 200 mg/m2, 1 h, d1, 22; CBP AUC = 4, d1, 22; 5-Fu 225 mg/m2/d, civ, d1–42 | 45 | 21.2 | 35% | – | – |